Implementing Maintenance and Reliever Therapy in adults with asthma aged 17 years and older in a primary care surgery over a 12-month period: Effects on inhaled corticosteroid prescribing, short-acting **β2-agonist** reliance and severe exacerbations

Parsons S, Trudgill J

Background

The number of adult patients with asthma \geq 17 years old prescribed inhaled corticosteroids (ICS) over a 12 month

Results


Asthma management in primary care may be neglected owing to time pressures, varied expertise, or a reluctance to change by health professionals and patients.

The Global Initiative for Asthma (GINA) supports using a single inhaler containing a low to medium dose inhaled corticosteroid (ICS) plus formoterol as a maintenance and reliever therapy (MART) in patients with asthma over 12 years old.


Aims



- Reduce inappropriate reliance on salbutariol (SABA) inhalers
- Reduce the risks of asthma exacerbations and the need for oral corticosteroids (OCS)



Number of adult patients with asthma aged ≥17 years issued 6+ SABA inhalers in the preceding 12 months



- (M) The number of patients prescribed an ICS increased from 340 (44% of adults with asthma) to 620 (82.2% of adults with asthma) in 12 months
- The proportion prescribed a high dose ICS reduced from 36% to 14.5%
- Patients issued with 6+ SABA inhalers reduced from 68 to 34 (50% reduction)
- There was a 39.5% decrease in number of the patients prescribed ≥ 2 courses of OCS in the preceding 12 months

Method

- Conducted a search of all adult patients aged ≥17 years old with a clinical code of asthma using the PrescQIPP Asthma Focus Audit Tool between 1 June 2023 and 1 June 2024.
- Measured the number of patients prescribed a high dose ICS as a proportion of all doses of ICS in the search group.
- number Measured the of patients issued 6 or more SABA inhalers in the last 12 months.
- number the Measured of patients 2 issued or more

Discussion

audit supports the change This SABA reliant asthma from favour in of management formoterol/ICS MART based therapies asthma to improve control reduce and severe exacerbations in a primary care setting.



courses of oral prednisolone in the preceding 12 months.

JUN-23 JUL-23 AUG-23 SEP-23 OCT-23 NOV-23 DEC-23 JAN-24 FEB-24 MAR-24 APR-24 MAY-24 JUN-24

1 June 2023 to 1 June 2024

Conference Abstracts | Primary Care Respiratory Society (pcrs-uk.org)

Contact details:

S Parsons, Salaried GP, Kennedy Way Surgery, Yate, Bristol. <u>sarah.parsons15@nhs.net</u>

J Trudgill, Paramedic practitioner, Kennedy Way Surgery, Yate, Bristol. jason.trudgill@nhs.net

NHS

Bristol, North Somerset and South Gloucestershire Integrated Care Board

References:

Levy, M.L., Beasley, R., et al (2024). A simple and effective evidence-based approach to asthma management: ICS-formoterol reliever therapy. *British Journal of General Practice*, 74(739), pp.86–89. doi:https://doi.org/10.3399/bjgp24x736353.

Global Initiative for Asthma (2023). *2023 GINA Main Report*. [online] Global Initiative for Asthma - GINA. Available at: https://ginasthma.org/2023-gina-main-report/. [Accessed 30 Jul. 2024].

www.prescqipp.info. (n.d.). *Bulletin 251: Asthma*. [online] Available at: https://www.prescqipp.info/our-resources/bulletins/bulletin-251-asthma/ [Accessed 30 Jul. 2024].

Transforming asthma care in the UK. (2022). Available at: https://www.asthmaandlung.org.uk/sites/default/files/Fighting%20back_V3.pdf. [Accessed 30 Jul. 2024].